Nuveen Asset Management, LLC Aerie Pharmaceuticals Inc Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $288,510 - $689,797	-45,292 Reduced 10.08%	404,020 $6.11 Million
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $321,621 - $595,161	64,974 Added 16.91%	449,312 $3.37 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $22,949 - $39,876	4,069 Added 1.07%	384,338 $3.21 Million
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $44,998 - $85,445	6,410 Added 1.71%	380,269 $2.67 Million
Q3 2021 Nov 12, 2021	SELL	$11.32 - $16.63 $620,086 - $910,958	-54,778 Reduced 12.78%	373,859 $4.26 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $1.01 Million - $1.27 Million	66,692 Added 18.43%	428,637 $6.86 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $587,618 - $936,069	-44,788 Reduced 11.01%	361,945 $6.47 Million
Q4 2020 May 17, 2021	SELL	$9.12 - $14.49 $221,479 - $351,889	-24,285 Reduced 5.63%	406,733 $5.5 Million
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $1.53 Million - $2.43 Million	-167,466 Reduced 27.98%	431,018 $5.82 Million
Q3 2020 Nov 16, 2020	BUY	$10.46 - $14.46 $123,365 - $170,541	11,794 Added 2.01%	598,484 $7.05 Million
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $937,476 - $1.26 Million	78,123 Added 15.36%	586,690 $8.66 Million
Q1 2020 May 14, 2020	BUY	$11.84 - $25.52 $2.96 Million - $6.37 Million	249,703 Added 96.46%	508,567 $6.87 Million
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $866,259 - $1.23 Million	48,886 Added 23.28%	258,864 $6.26 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $237,268 - $360,864	12,888 Added 6.54%	209,978 $4.04 Million
Q2 2019 Aug 15, 2019	BUY	$28.97 - $48.21 $5.71 Million - $9.5 Million	197,090 New	197,090 $5.82 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account